Showing results (61-70 of 233) with videos related to
Sort By:
Pageof 24
Journal of the American College of Cardiology|October 8, 1997
Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) StudyF Kontny, J Dale, U Abildgaard, et al.The Journal of Heart Valve Disease|May 4, 1999
Recurrent endocarditis in silver-coated heart valve prosthesisH K Kjaergard, J Tingleff, U Abildgaard, et al.Thrombosis and Haemostasis|April 30, 1976
The effect of antithrombin III on the activity of the coagulation factors VII, IX and XB Osterud, M Miller-Andersson, U Abildgaard, et al.Thrombosis and Haemostasis|December 27, 1982
Inhibition of activated coagulation factor VII by normal human plasmaP E Dahl, U Abildgaard, M L Larsen, et al.Haemostasis|January 1, 1989
Extrinsic pathway inhibitor in postoperative/posttraumatic septicemia: increased levels in fatal casesP M Sandset, O Røise, A O Aasen, et al.The American Journal of Physiology|December 1, 1988
Intrarenal blood flow distribution in dog kidney determined by 99mTc microaggregates and 201TlU Abildgaard, O Amtorp, J Gyring, et al.Thrombosis Research|June 1, 1987
Monitoring of heparin therapy: should heparin assays also reflect the patient's antithrombin concentration?H A Holm, U Abildgaard, M L Larsen, et al.Thrombosis Research. Supplement|January 1, 1991
Involvement of the extrinsic pathway in the activities of low molecular weight heparinsL Norrheim, U Abildgaard, M L Larsen, et al.Thrombosis Research|November 15, 1996
Binding of tissue factor pathway inhibitor to cultured endothelial cells-influence of glycosaminoglycansN Iversen, P M Sandset, U Abildgaard, et al.Thrombosis and Haemostasis|December 19, 1980
Isolation and characterization of heparin from human mastocytoma tissueL Thunberg, M Höök, U Lindahl, et al.Pageof 24